Discovery of ONO-8590580: A novel, potent and selective GABAA α5 negative allosteric modulator for the treatment of cognitive disorders was written by Lewis, A.;Beresford, A.;Chambers, M. S.;Clark, G.;Hartley, D. C.;Hirst, K. L.;Higashino, M.;Kawahadara, S.;Nakanishi, M.;Saito, T.;Imagawa, A.;Habashita, H.;Maidment, S.;Macleod, A. M.;Owens, A. P.;Rae, A.;Rouse, C.;Wishart, G.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2020.Related Products of 25676-75-9 This article mentions the following:
The identification and SAR development of a series of neg. allosteric modulators of the GABAA α5 receptor is described. This novel series of compounds was optimized to provide analogs with high GABAA α5 binding affinity, high α5 neg. allosteric modulatory activity, good functional subtype selectivity and low microsomal turnover, culminating in identification of ONO-8590580(I). In the experiment, the researchers used many compounds, for example, 4-Bromo-1-methylimidazole (cas: 25676-75-9Related Products of 25676-75-9).
4-Bromo-1-methylimidazole (cas: 25676-75-9) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. The pharmacophore of imidazole exists in bioactive compounds including amino acids, plant growth regulators and therapeutic agents.n increase of the alkyl chain length of the alcohols. Related Products of 25676-75-9
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem